Circulation
-
Randomized Controlled Trial
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
There is a modest risk of myocardial infarction (MI) and myocardial ischemic events in patients with atrial fibrillation. ⋯ There was a nonsignificant increase in MI with dabigatran compared with warfarin, but other myocardial ischemic events were not increased. Treatment effects of dabigatran were consistent in patients at higher and lower risk of myocardial ischemic events.